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Background and Objectives: Both enchondroma and atypical cartilaginous tumors (ACT) are not considered malignant, so inactive and
asymptomatic tumors might not need surgery. To the best of our knowledge, this is the ﬁrst study that has been done to evaluate the natural course of
conservative-treated enchondroma and ACT in the long bones.
Methods: For this retrospective study, we analyzed the results of patients in whom we refrained from surgery and only regularly performed
radiological follow-up of the tumor. Minimal follow-up after initial diagnosis was 24 months.
Results: Forty-nine patients were included in this study. Eight out of forty-nine cases received surgical treatment during follow-up of the tumor.
The reasons for this surgery were radiologic growth of the tumor in two cases, pain in one case, patient request in three cases, another indication for
surgery in the same limb in two cases.
Conclusion: In this small series of conservatively treated enchondroma and ACT, only 6% of the patients had amedical indication for surgery. This
study shows that indication for surgery should be discussed more thoroughly. Based on our results, we would recommend annual radiologic follow-
up for asymptomatic enchondroma or ACT in the long bones, irrespective of tumor size.
J. Surg. Oncol. 2016;114:987–991.  2016 Wiley Periodicals, Inc.
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INTRODUCTION
Enchondroma and chondrosarcoma are common bone tumors that
typically occur central in the medullary cavity in any bone originating
from enchondral ossiﬁcation. They are characterized by tumor cells
producing cartilaginous matrix.
In the current 2013World HealthOrganization (WHO) classiﬁcation
system, grade 1 chondrosarcoma has been renamed as “atypical
cartilaginous tumors” (ACT) better describing its clinical behavior [1].
ACT rarely metastasizes and therefore it is now classiﬁed as an
intermediate type of tumor, not a malignancy [2,3].
Due to more frequent imaging, for example, radiographs and MRI
scans, accidental ﬁndings of enchondroma and ACT have become more
common [4,5]. This often leads to referral of the patient to an orthopedic
oncologic center for further diagnostics and treatment advice.
To distinguish enchondroma from ACT on conventional
radiographs and MRI is often difﬁcult, especially when the lesion
is located in the long tubular bones [6–12]. This may result in
signiﬁcant overtreatment of benign lesions in case of enchondroma
being diagnosed as ACT. Or it results in under treatment in case of
ACT being diagnosed as enchondroma and erroneously discharged
from follow-up. Histological differentiation between enchondroma
and ACT depends on subtle criteria and malignant features could
easily be missed by a biopsy due to the heterogeneity of cartilaginous
tumors [9,13].
Terms as borderline chondrosarcoma and chondrosarcoma grade 1/2
have been used for lesions with some radiographic malignant
characteristics, but with insufﬁcient histological signs to conﬁrm the
diagnosis chondrosarcoma [14]. Dahlin used these terms to alert
surgeons not to over treat this group of patients. Nowadays these terms
have generally been abandoned.
The current surgical treatment for small, central enchondroma and
ACT in long bones that are conﬁned to the bone is intralesional
curettage with local adjuvant therapy. Reported complications of
curettage and local adjuvant treatment in enchondroma and ACT are
postoperative fractures, infection, and local recurrence [15,16].
Enchondromas are benign lesions that do not need surgical treatment
if inactive and symptomless [10,17]. It is estimated that approximately
4% of solitary enchondromas change into secondary chondrosarcoma,
indicating that follow-up is needed [18].
Many authors have proposed radiographic follow-up instead of
surgery for cartilaginous tumors in the long bones without signs of local
aggressiveness [6,7,19,20]. Radiographic follow-up instead of surgery
may prevent over treatment of this group of patients, resulting in less
morbidity and lesser costs.
However, to the best of our knowledge no study has yet been
performed showing the results of radiological follow-up.
The aim of our study was to evaluate the natural course of
enchondroma and ACT through active surveillance. This study is
approved by the medical ethical committee. To the best of our
knowledge, this is the ﬁrst study that has been done to evaluate the
natural course of conservatively treated enchondroma and ACT in the
long bones.
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PATIENTS AND METHODS
To evaluate the natural course of enchondroma and ACT of the long
bones, we analyzed the results of conservatively treated patients in
which we refrained from surgery and only did regular follow-up of the
lesion.
In this study, we included conservatively treated patients with
enchondroma or ACT, who were under radiologic follow-up in
Radboudumc between 2008 and 2013. Conservative-treated patients,
with enchondroma or ACT, were retrospectively selected by using a
record of all patients seen in our hospital.
Inclusion criteria were conservatively treated patients with
enchondroma or ACT, at least 18 years old, with lesions in the long
bones of the extremities and a follow-up time of minimal 24 months
since initial diagnosis. Patients with Ollier disease, Maffucci syndrome,
or high grade chondrosarcoma were excluded. Forty-nine cases met the
inclusion criteria and were included in our study.
All lesions were evaluated at diagnosis using physical examination,
plain radiographs, and MR-imaging. Whenever cases were referred to
our hospital, all imaging was reviewed by our experienced
musculoskeletal radiologist. Standardized techniques were used for
plain radiographs in all cases.
In a few early cases, a trocar biopsy was performed, either in the
referral hospital or in our hospital, before a treatment advice was given.
Nowadays biopsies are no longer performed in our hospital for this
cause since histological diagnosis is not reliable.
Due to the similarity of imaging characteristics of enchondroma and
ACT on conventional radiographs and MRI, no difference could be
made and all cases diagnosed based on only imaging methods were
diagnosed as enchondroma/ACT.
Malignant radiologic characteristics used to indicate
chondrosarcoma grade 2 or grade 3 were cortical destruction,
presence of soft tissue mass, moth-eaten or permeative osteolysis,
pluri-lamellar or speculated periosteal reaction [10,19,21]. Based on
these malignant characteristics, differentiation between high grade
chondrosarcoma and enchondroma/ACT was made (see Figs. 1 and 2).
When no invalidating pain and no radiographic signs of malignancy
were seen, active surveillance was advised to the patient. Patients who
approved through verbal consent, with active surveillance, were
followed-up with aMRI scan after 6months. If theMRI scan showed no
growth of the tumor or other radiological changes, radiologic follow-up
was continued every 1–2 years. Increased calciﬁcation was excluded as
growth of the lesion. Radiologic follow-up consisted of conventional
radiographs or MRI depending on interpretability of the tumor on
conventional radiographs.
All patients who were managed by active surveillance were
instructed to contact our hospital in case of new or increased pain. In
case of new or increased pain complaints, physical examination and
radiologic assessment were performed to rule out other sources of
pain.
Whenever invalidating pain or radiographic changes occurred or the
patients revised their choice for conservative therapy, patients were
treated with surgery. The following operating technique was used in all
cases treated with surgery. An oval-shaped cortical window was made
with a high speed burr, after which the lesions were thoroughly
curettaged followed by three cycles of cryosurgery with rapid freezing
of at least50°C and slow thawing. After cryosurgery, the bony defects
were ﬁlled up with either bone graft or bone cement. In diaphyseal
lesions, prophylactic plating was performed to prevent postoperative
fractures. All operated cases stayed under follow-up after surgery.
RESULTS
A total of 49 cases (27 female and 22male patients) met the inclusion
criteria for this study.Mean age at diagnosis was 49 years (range: 20–76
years). See Table I for patient demographics.
Thirty-three of the forty-nine cases (67%) were ﬁrst diagnosed in
another hospital and were referred to our hospital for further analysis.
In 5 of the 49 cases (10%), a trocar biopsy was performed to conﬁrm
the diagnosis. After biopsy, four of these ﬁve cases were diagnosed
histopathologically as enchondroma and one case was diagnosed as
Fig. 1. SE T1-weighted contrast-enhanced sagittal image with fat
saturation of a 65-year-old woman shows a 4 cm intramedullary
lobulated tumor with septal and rim enhancement abutting the posterior
cortex. No surrounding edema or periosteal reaction. Histologically
proven ACT.
Fig. 2. SE T1-weighted contrast-enhanced sagittal image with fat
saturation of a 40-year-old woman shows predominantly irregular rim
enhancement. There is vast cortical destruction with extensive soft
tissue involvement as well as intra-articular extension. Histologically
proven chondrosarcoma grade 2.
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ACT. In 44 out of 49 cases (90%), no biopsy was performed and the
diagnosis was based on clinical examination and radiographic
appearance, conventional radiographs, and MRI. All those 44 cases
were diagnosed as enchondroma/ACT due to the similarity of those
tumors on imaging methods.
Mean follow-up time since initial diagnosis was 66 months (range:
25–213 months).
All patients are current on their surveillance imaging, no patients
were lost to follow-up.
Clinical Presentation
Forty-three of the cases (88%) were incidental ﬁndings and two (4%)
presented themselves with pain complaints. Of the remaining four cases
(8%), the referral indication was unknown, all these cases were
diagnosed more than 10 years ago.
Radiological Follow-Up
In 8 of the 49 cases (16%), there was a radiologic change of the
lesion noticed during follow-up. All eight cases presented with
growth of the lesion, none presented scalloping or cortical
breakthrough. Mean time between initial diagnosis and change of
the lesion was 41 months (range: 20–76 months). The only case
histopathologically diagnosed as ACT showed no radiologic changes
2 years after biopsy.
Both cases that presented with pain complaints showed no radiologic
changes.
Secondary Surgery
Eight of the forty-nine cases (16%) underwent surgical treatment
during follow-up (Table II). Mean time between initial diagnosis and
surgical treatment was 37 months (range: 21–57 months). The reasons
for surgery were radiological change of the lesion in two cases,
invalidating pain in one case, patient request in three cases, and total
knee arthroplasty (TKA) due to osteoarthritis combined with curettage
of the lesion in two cases.
All cases operated on have been under follow-up after surgery. No
recurrence of the tumor is seen in these cases. Mean time between
surgery and last follow-up was 12 months (range: 1–44 months).
Four out of eight cases (50%) that showed radiological change have
been operated. Two cases were operated because of radiologic change
during follow-up and in two cases minimal growth (<5mm) was
detected and surgery was requested by the patient.
Four out of eight cases (50%) showed radiological change but were
not operated on. All four cases showed minimal growth, ranging from 3
to 8mm.
In 37 of the 49 cases (73%), there was no change observed during
follow-up, on conventional radiographs or MRI, or any other reason to
perform surgery.
DISCUSSION
The purpose of this study was to evaluate the natural courses of
enchondroma and ACT in the long bones by active surveillance. To the
best of our knowledge, this is the ﬁrst study that evaluates the natural
course of enchondroma and ACT.
Performing radiographic monitoring for both enchondroma and
ACT is in accordance with Crim et al. [6] who recommend serial
follow-up rather than curettage for non-painful cartilaginous lesions of
any size due to problematic imaging criteria for both enchondroma and
ACT. Campanacci et al. [20] recommend that small (<5 cm),
asymptomatic, intraosseous cartilaginous lesions of long bones
without radiological signs of local aggressiveness should be observed
as benign enchondroma, and no surgery or further investigations other
than serial follow-up is indicated.
Surgical treatment of ACT of the long bones has been a subject of
debate for the last decades. In our hospital, curettage with cryosurgery
TABLE I. Patient Demographics
Variable No (%)
Mean age (range, years) 49 (20–76)
Mean follow-up (range, months) 67 (25–213)
Gender
Male 22 (45)
Female 27 (55)
Location
Distal femur 33 (67)
Proximal femur 3 (6)
Proximal humerus 8 (16)
Proximal tibia 3 (6)
Distal tibia 1 (2)
Proximal fibula 1 (2)
Size
<2 cm 7 (14)
2–5 cm 23 (47)
5–10 cm 17 (35)
10–15 cm 1 (2)
15–20 cm 1 (2)
TABLE II. Cases Operated During Follow-Up
Referral
indication Location
Initial
size
in cm Reason for surgery
Time in months
from diagnosis to
surgery
Prophylactic
plating used
Radiologic
diagnosis before
surgery
Pathologic
diagnosis
after surgery
Incidental Distal tibia 3.2 Radiologic growth
(0.6 cm)
53 No Ech/ACT ACT
Incidental Distal femur 4.6 Radiologic growth
(1.0 cm)
44 Yes Ech/ACT ACT
Incidental Distal femur 20.0 Pain 10 Yes Ech/ACT Ech
Incidental Proximal
tibia
4.7 Choice patient 34 Yes ACT Ech
Incidental Proximal
tibia
6.0 Choice patient 21 Yes Ech/ACT Ech
Incidental Proximal
tibia
1.7 Choice patient 48 No Ech/ACT Haemangioma
Incidental Distal femur 3.2 Total knee arthroplasty 57 No Ech/ACT Ech
Incidental Distal femur 2.7 Total knee arthroplasty 30 No Ech/ACT Ech
Ech, enchondroma; ACT, atypical cartilaginous tumor.
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has been the treatment of choice for ACT [16]. Curettage and local
adjuvant treatment is also considered as adequate treatment according
to the 2013 WHO standard [1]. Postoperative fractures, infection, and
local recurrence have been reported to be complications after curettage
and local adjuvant treatment. The low rate of transformation to higher
grade of malignancy and rare metastases of enchondroma and ACT
implicates that these lesions might not need surgery.
A malignant transformation rate of 4% for enchondroma was
reported by Altay et al. [18]. In their study, 6 out of 143 cases of
enchondroma underwent malignant transformation, 5 had changed into
ACT, and only 1 case transformed into grade 2 chondrosarcoma.
Schwab et al. [22] reported a malignant transformation rate of ACT in
the long bones in only 4 of 164 patients. Andreou et al. [23] reported a
malignant transformation of ACT of 0% in the upper extremity and of
6% in the lower extremity. Only cases that transformed to grade 2
chondrosarcoma developed metastases. This low malignant
transformation rate is in accordance with our study where none of
the included lesions transformed into high grade chondrosarcoma.
In the present study, we found that only 3 of the 49 cases (6%) had a
medically grounded indication for removal of the lesion, being
invalidating pain or radiographic changes as described in Table II.
The longer follow-up time before surgery had no consequences for
the surgical procedure or the rehabilitation process. All cases operated
on were treated with curettage and cryosurgery. None of the patients
included in this study suffered from local complications, for example,
pathologic fractures during follow-up.
Selection of patients for conservative therapy is important. We were
careful to exclude all tumors that were not clearly enchondroma or
ACT, that is, showed radiological signs of high grade chondrosarcoma.
Other studies showed that distinction between low and high-grade
chondral lesions can be safely determined based on MR-imaging,
without the need for pre-operative biopsy [24,25]. We also excluded
lesions of the axial skeleton because of the worse prognosis compared to
lesions in the long bones [2,23,26,27].
With only 6% of the studied cases needing surgery, this study shows
that indication for surgery should be discussed more thoroughly. As the
reported complications after curettage are considerable, surgery should
be conﬁned to tumors with substantial risk of malignant transformation
or metastasis.
However, in case of conservative therapy, there is, to our knowledge,
no evidence in the literature for follow-up frequency and duration of
follow-up. In our study, mean time between initial diagnosis and
radiologic change of the lesion was 41 months with a wide range of
20–76 months and the mean time between initial diagnosis and surgery
was 37 months (range: 10–57 months).
The study of Herget et al. [28] showed that the time between the
initial diagnosis of enchondroma and the diagnosis of malignancy
varied between 6 months and up to 30 years. This indicates that
enchondroma and ACT lesions might proﬁt from a lifelong radiological
follow-up. Brien et al. [5] recommend a follow-up of at least two
decades for solitary enchondroma of the long bones if detected after
age 25.
The frequency of skeletal imaging must be outweighed against the
risk of cumulative radiation exposure.
Herget et al. [28] recommend annual clinical and annual/biennial
MRI examination for the follow-up of asymptomatic enchondroma
localized in the long bones,>5 to 6 cm. Annual clinical and bi-/triennial
radiological examination (plain radiographs, in any doubtMRI) follow-
up is recommended for asymptomatic enchondroma lesions<5 to 6 cm.
Parlier-Cuau et al. [19] recommend radiologic follow-up once a year for
inactive lesions. Based on our results, we would recommend
conservative treatment for asymptomatic enchondroma or ACT in
the long bones, irrespective of tumor size. Geinaerdt reports that only in
the axial skeleton, tumors larger than 4–6 cm are generally
malignant [10]. Radiologic follow-up is necessary, based on our
experience we recommend annual MR-imaging. MR-imaging is
recommended because it is better in correct tumor measurement
compared to radiographs [10,21]. Since growth of the tumor is one of
the criteria to decide for operation, the correct measurement of tumor
size is of high importance. When no changes occur during follow-up of
at least 2 years, frequency of MR-imaging can be reduced to every 2–3
years. More research should be done to make an international protocol
for optimal radiological follow-up of enchondroma an ACT.
The results of this study should be interpreted with some caution as
this study had some limitations. Due to the rarity of these tumors, the
size of the group studied was small and follow-up in this study was
relatively short. Considering the slow biological progression of
echondroma and ACT, it is not possible to make deﬁnite conclusions
about the oncological outcome.
In only 5 of the 49 cases, diagnosis was conﬁrmed by biopsy, in the
other cases diagnosis was made based on radiographic appearance,
conventional radiographs, and MRI. In these 44 cases, no difference
could bemade betweenACTor enchondroma. Thismeans that the exact
number of enchondroma and ACT cases included in this study is
therefore not known.
CONCLUSION
In this small series of conservatively treated enchondroma and ACT,
only 6% of the studied cases had a medically grounded indication for
surgery. None of the surgically treated lesions was transformed into a
high grade chondrosarcoma. This study shows that indication for
surgery should be discussed more thoroughly. Based on our results, we
would recommend annual radiologic follow-up for asymptomatic
enchondroma or ACT in the long bones, irrespective of tumor size.
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